Palisade Bio Reports First Patient Enrollment in P-III Study of LB1148 for Postoperative Return of Bowel Function
Shots:
- The first patient has been screened in the P-III study evaluating the safety & efficacy of LB1148 in ~600 adult patients undergo a scheduled bowel resection surgery incl. laparotomy or laparoscopic surgical approaches
- The 1EPs of the study is a time for recovery of the upper & lower gastrointestinal tract following surgery. The trial will make use of the same dosage of LB1148 as was utilized in the P-II study which demonstrated a 1.1-day improvement in return bowel function
- LB1148 is a novel oral liquid formulation of digestive enzyme inhibitor tranexamic acid to minimize abdominal adhesions & restore bowel function following surgery. The treatment is now being developed to be used before surgeries that are at risk of disrupting the intestinal epithelial barrier
Ref: GlobalNewswire | Image: Palisade Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
